Head-to-head · Cost-Efficiency Index
Peptivo vs Wisp
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Peptivo
Shoppers who value verifiable named pharmacy and medical-leadership credentials, willing to complete an intake quiz to see final pricing.
Visit PeptivoWisp
Cost-first shoppers who want branded injectables plus a sublingual semaglutide alternative.
Visit WispThe verdict
Peptivo and Wisp tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with Peptivo (ranked #199, a hair above #202) — Shoppers who value verifiable named pharmacy and medical-leadership credentials, willing to complete an intake quiz to see final pricing. But Wisp is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Peptivo.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Peptivo | Wisp |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $169/mo (compounded) | $225/mo (compounded oral) |
| Tirzepatide / mo | $249/mo (compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,028 | $2,700 |
| Tirzepatide / yr (modeled) | $2,988 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Yes |
| Rank here | #199 | #202 |
Peptivo
63/100Where the value is
- Four named, verifiable compounding pharmacy partners across multiple states
- Named Chief Medical Innovation Officer (MD) and VP of Pharmacy Operations, plus a physician advisory board
- Ships to all 50 states
The tradeoffs
- Exact GLP-1 pricing gated behind an intake quiz, not shown as a static table
- Company's own sibling NAD+ products use a first-month-then-higher pricing structure, raising unconfirmed suspicion the GLP-1 pricing may work the same way
Wisp
63/100Where the value is
- Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
- LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
- Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary
The tradeoffs
- The $99/mo tirzepatide figure is a consultation-and-care subscription, not the medication: Zepbound is filled at a pharmacy of your choice at its own cost, which Wisp does not publish
- The compounded semaglutide option is sublingual drops, which Wisp itself describes as less effective than injection
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.